[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] #  @andrewcaravello Andrew Caravello, DO Andrew Caravello, DO posts on X about $nwbo, $ibrx, science, the first the most. They currently have XXXXX followers and XX posts still getting attention that total XXX engagements in the last XX hours. ### Engagements: XXX [#](/creator/twitter::244291506/interactions)  - X Week XXXXXX +76% - X Month XXXXXX -XX% - X Months XXXXXXX -XX% - X Year XXXXXXXXX +3,261% ### Mentions: XX [#](/creator/twitter::244291506/posts_active)  - X Week XX +24% - X Month XX +13% - X Months XXX +437% - X Year XXX +1,588% ### Followers: XXXXX [#](/creator/twitter::244291506/followers)  - X Week XXXXX +4.90% - X Month XXXXX +6.90% - X Months XXXXX +69% - X Year XXXXX +170% ### CreatorRank: XXXXXXXXX [#](/creator/twitter::244291506/influencer_rank)  ### Social Influence **Social category influence** [finance](/list/finance) XXXX% **Social topic influence** [$nwbo](/topic/$nwbo) #2, [$ibrx](/topic/$ibrx) #7, [science](/topic/science) 3.85%, [the first](/topic/the-first) 3.85%, [future](/topic/future) 3.85%, [balance sheet](/topic/balance-sheet) #1438, [$4205t](/topic/$4205t) #78, [cuomo](/topic/cuomo) 1.92%, [elements](/topic/elements) 1.92%, [the face](/topic/the-face) XXXX% **Top accounts mentioned or mentioned by** [@jimtanaka1](/creator/undefined) [@_littlefire1](/creator/undefined) [@dcvaxdefender](/creator/undefined) [@stephenwangs73](/creator/undefined) [@maveric92283613](/creator/undefined) [@smyley4evr1](/creator/undefined) [@metacollectiveg](/creator/undefined) [@drmakaryfda](/creator/undefined) [@ottopichler](/creator/undefined) [@scooterd_speaks](/creator/undefined) [@flyfishing15331](/creator/undefined) [@alphavestcap](/creator/undefined) [@doc_brown2](/creator/undefined) [@grok](/creator/undefined) [@littlefire1](/creator/undefined) [@nocontextbrits](/creator/undefined) [@ustraderep](/creator/undefined) [@commercegov](/creator/undefined) [@potuss](/creator/undefined) [@drpatsoonshiong](/creator/undefined) **Top assets mentioned** [ImmunityBio, Inc. Common Stock (IBRX)](/topic/$ibrx) ### Top Social Posts Top posts by engagements in the last XX hours "#MHRA Please approve $NWBO #DCVax for #GBM. Patients need access to better treatments and DCVax has already shown meaningful survival benefit with essentially no toxicity. It is time 🎄 The only real toxicity left is the delay. Patients and families deserve access now" [X Link](https://x.com/andrewcaravello/status/1996645327588442120) 2025-12-04T18:18Z 1417 followers, 2757 engagements "🧬 $NWBO 424B5 FORENSIC INTELLIGENCE REPORT ➡ TLDR The 424B5 NWBO filed on November XX 2025 is the opposite of a distressed financing. It is a regulatory-blackout pre-approval institutional-ready launch document. Across XX pages NWBO: Adds no new risk factors meaning no negative MHRA feedback existed. Repeats forward-looking disclaimers classic posture of a company expecting a material regulatory decision very soon after filing. Shows zero near-term dilution pressure in the 424B5 only 21.7M reserve shares NTBV unchanged; future A/S headroom is addressed separately in the proxy as a governance" [X Link](https://x.com/andrewcaravello/status/1993480956426977289) 2025-11-26T00:44Z 1412 followers, 12.9K engagements "The NewsNation special is not scientific evidence. It was a sponsored primetime feature centered entirely around Patrick Soon Shiong and multiple outlets have already confirmed that the program was produced in coordination with his company $IBRX. That is why the segment relied on dramatic storytelling emotional interviews and bold claims rather than controlled clinical data. Cuomo is not a scientific reviewer and NewsNation is not a peer reviewed journal. When you strip away the television format every major claim in that segment falls into one of two categories. Either it was a personal" [X Link](https://x.com/andrewcaravello/status/1995183558814531596) 2025-11-30T17:30Z 1413 followers, 40.5K engagements "$IBRX The Journal of Urology paper is meaningful for patients with papillary-only NMIBC and no one disputes that bladder preservation is important. But the paper only presents one part of the story and that context matters when discussing FDA policy. The publication covers Cohort B only where #Anktiva was given with BCG intravesically in a very specific localized disease setting. There was no control arm and the outcomes reported in Cohort B are essentially the same outcomes historically seen with BCG alone in papillary disease. If a combination produces the same results as BCG monotherapy" [X Link](https://x.com/andrewcaravello/status/1996246550528352691) 2025-12-03T15:54Z 1412 followers, 3124 engagements "Combination therapy is a valid idea in oncology but even with combinations you still have to show what each component is actually contributing. When both elements are delivered together in a single arm study and one of them is a very active backbone like BCG the design does not let you determine how much of the outcome came from the backbone and how much from the add on. That is not a criticism. It is simply how contribution of effect is established in cancer trials. This is exactly why the FDA noted that the study design limited their ability to say what Anktiva itself was adding. If the" [X Link](https://x.com/andrewcaravello/status/1996321765367460317) 2025-12-03T20:52Z 1411 followers, XXX engagements "🧬 The Shape of What Comes Next: How the 2025 GBM Vaccine Review Redefined the Science of $NWBO #DCVax Dendritic-Cell Immunotherapy TLDR In late 2025 Cancers (MDPI) published a sweeping unusually comprehensive review on glioblastoma vaccination titled Combined Tumor Cell and Lysate-Based Vaccines for Immunotherapy of Primary and Recurrent Glioblastoma (GBM). For the first time in a major peer-reviewed venue a scientific team laid out a full mechanistic blueprint explaining why glioblastoma has resisted nearly every conventional immunotherapy and what biological principles a successful vaccine" [X Link](https://x.com/andrewcaravello/status/1993708127342973385) 2025-11-26T15:47Z 1416 followers, 1776 engagements "⚠Why Treating #ALC With IL-15 Does Not Cure Cancer And why the $IBRX BioShield thesis collapses in the face of immunology clinical evidence and $NWBO #DCVax biology #Lymphopenia is a recognized diagnosis. It has an ICD code. But treating absolute lymphocyte count (ALC) as if the number itself were the disease fundamentally misinterprets medicine and immunology. Lots of lab abnormalities have ICD-10 codes: Anemia Leukopenia Thrombocytopenia Electrolyte disturbances A diagnostic code does not mean the lab value is the therapeutic target. It simply means the abnormality needs evaluation not" [X Link](https://x.com/andrewcaravello/status/1994659258265206820) 2025-11-29T06:46Z 1415 followers, 11.8K engagements "The XX percent youre quoting isnt the effect of $IBRX #Anktiva. Its the effect of BCG. In the pivotal trial every CIS patient received BCG plus Anktiva and the FDA states plainly that you cannot statistically separate which drug did what. Thats why the agency also wrote that the median duration of response is not a reliable estimate because nearly two thirds of responders were censored. When Anktiva was tested without BCG in Cohort C the response rate was zero. And when BCG alone was compared to BCG plus a strong immunotherapy in the randomized ALBAN trial the curves were identical and the" [X Link](https://x.com/andrewcaravello/status/1994893748510101916) 2025-11-29T22:18Z 1416 followers, XXX engagements "@NoContextBrits The Cure for cancer. $NWBO #DCVax" [X Link](https://x.com/andrewcaravello/status/1995260275243507889) 2025-11-30T22:34Z 1416 followers, 1303 engagements "The Turning of the Gate: How the USUK Drug Pricing Pact Reshapes $NWBO #DCVax Commercial Landscape The December X 2025 USUK pharmaceutical pricing agreement represents more than a trade compromise. It marks the moment Britain rewired its economic architecture for Advanced Therapy Medicinal Products (ATMPs) creating a reimbursement environment built for therapies with durable survival curves and long-tail benefit. The policy never mentions DCVax-L by name. It did not need to. The agreements structural adjustments align so precisely with Northwest Biotherapeutics (NWBO) positioning that the" [X Link](https://x.com/andrewcaravello/status/1995633792514408792) 2025-12-01T23:19Z 1416 followers, 5131 engagements "What the data actually show is that $IBRX #Anktiva on its own did not just fail to help. In many cases it produced outcomes worse than what you would expect from BCG alone. That is the central fact everything else has to orbit. If a drug claims to restore or boost immune cells yet performs below the historical baseline of BCG then the biology is not behaving the way the mechanism promises. It is that simple and that fundamental. This mirrors the same clinical principles used across medicine. You do not treat a number. A hemoglobin of X means hemorrhage in trauma renal failure in chronic" [X Link](https://x.com/andrewcaravello/status/1996528187338010759) 2025-12-04T10:33Z 1415 followers, 1290 engagements "🧬 $NWBO #DCVax and the Map of the Neutrophil World How a Single Nature Paper Quietly Validated the Myeloid Logic of DCVax TL;DR A new Nature paper has built the first true map of the neutrophil world (NeuMap) a universal coordinate system showing that neutrophils move between a small number of predictable functional hubs depending on cytokine signals. Tumors hijack this map by pulling neutrophils into two suppressive pro-angiogenic hubs (IS-I and IS-II). Interferons pull them into anti-tumor hubs. Under the right conditions neutrophils can even become antigen-presenting cells (APCs).123 Once" [X Link](https://x.com/andrewcaravello/status/1996644069368283364) 2025-12-04T18:13Z 1416 followers, 1600 engagements "$NWBO #DCVax stands out even more under the new HHS AI Strategy HHS just unveiled its AI plan and it changes everything about how cancer data will be analyzed If you handed an AI every cancer study and told it to answer one question What actually works it would see the pattern immediately Most oncology drugs create small fragile gains with high toxicity #NWBO #DCVax produces durable immune control across tumors with almost none An AI trained to merge trial data real world evidence and survival curves would flag the same signal again and again Long tail survivors Consistent effect across" [X Link](https://x.com/andrewcaravello/status/1996675832329433332) 2025-12-04T20:19Z 1416 followers, 1716 engagements "You actually can say patients do just as well and sometimes better with proper BCG re-induction because the actual numbers support it. Many people labeled BCG-failed arent biologically refractory; they simply didnt meet the response window after their first induction. When those same patients receive a true second induction of BCG outcomes are strong. In a modern multi-center study XXXX% of re-induced patients achieved a complete response and XXXX% of those responders remained disease-free at XX months. The MSK double-induction protocol showed even stronger results: XX% complete response at 6" [X Link](https://x.com/andrewcaravello/status/1996773559121637588) 2025-12-05T02:48Z 1416 followers, XX engagements "I get the frustration but the FDA is actually showing its hand here. The Plausible Mechanism Pathway was co written by the current FDA Commissioner and published in the NEJM. It was designed for platforms with a clear mechanism plus real world evidence. That is exactly where $NWBO sits with a completed pivotal Phase III and years of expanding RWE. The agency is not lowering the bar. It is shifting to a framework that DCVax L already fits one that allows real world evidence to support tissue agnostic deployment" [X Link](https://x.com/andrewcaravello/status/1996946031448048101) 2025-12-05T14:13Z 1416 followers, XXX engagements "Cant disagree with that 😅 Its a good thing LP chose the UK for first approval. The MHRA has already built the framework for RWE driven tissue agnostic immunotherapies and DCVax fits that model better than anything in big pharmas pipeline. The move protected the science and positions NWBO to come back to the FDA from a position of strength" [X Link](https://x.com/andrewcaravello/status/1996948563662692689) 2025-12-05T14:23Z 1415 followers, XX engagements "Youre absolutely right to ground this conversation in Jim Allisons work because CTLA-4 blockade only succeeds when tumor antigens are already being properly presented. That is why CTLA-4 and PD-1 inhibitors produce long-tail survival in melanoma and other cancers. They do not make the immune system stronger. They remove brakes from an immune system that already recognizes the tumor. That recognition step is the key difference between checkpoint blockade and an IL-15 agonist. This is exactly the principle the UCLA group including Liau Prins and Mulholland has spent their careers building on." [X Link](https://x.com/andrewcaravello/status/1997100641320112600) 2025-12-06T00:27Z 1415 followers, XX engagements "🧬 #FDA Just Revealed the Exact Pathway $NWBO #DCVax-L Needs The new FDA Grand Rounds isnt about DCVax but it is about the regulatory engine DCVax-L runs on. On December XX the Agency is dedicating an entire session to Real-World Evidence (RWE)how to validate it how to judge external controls and how to use it in oncology approvals when traditional RCTs are impossible. That matters because DCVax-Ls Phase X trial used: an external control arm a crossover-contaminated dataset and survival outcomes proven through RWE-strength comparisons The invited speaker Dr. Marie Bradley is the FDAs senior" [X Link](https://x.com/andrewcaravello/status/1996015113673797986) 2025-12-03T00:34Z 1417 followers, 8357 engagements "$NWBO #DCVax and the Making of Eden How Zeon Edge Curate and Sawston Rebuilt the Future of Immunotherapy From the outside Northwest Biotherapeutics has long appeared easy to dismiss. The name is cumbersome. The companys balance sheet rarely invited envy. Analysts accustomed to clean small-molecule pipelines saw instead a Phase III glioblastoma trial that defied conventional oncology norms wrapped inside a cell therapy so personalized and so delicate that even well-capitalized companies have struggled to scale anything like it. To many the story looked familiar: an interesting data set some" [X Link](https://x.com/andrewcaravello/status/1996428219403145713) 2025-12-04T03:55Z 1416 followers, 1850 engagements "@maveric92283613 @maveric92283613 this narrative I posted is actually based on the court filing" [X Link](https://x.com/andrewcaravello/status/1997010621859316106) 2025-12-05T18:30Z 1417 followers, XXX engagements "This entire claim has no basis in evidence and none of the statements being made about N-803 are supported by clinical data regulatory filings or basic immunology. $IBRX #Anktiva is an IL-15 agonist that expands NK and CD8 cells but immune expansion is not the same as curing cancer clearing viruses fixing antibiotic resistance or extending human lifespan. In every cancer where outcomes can be compared to a known backbone N-803 has failed to show any independent therapeutic effect. In pancreatic cancer it matched third-line chemotherapy. In NSCLC it matched treatment-beyond-progression on" [X Link](https://x.com/andrewcaravello/status/1997261707253555578) 2025-12-06T11:07Z 1417 followers, XXX engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@andrewcaravello Andrew Caravello, DO
Andrew Caravello, DO posts on X about $nwbo, $ibrx, science, the first the most. They currently have XXXXX followers and XX posts still getting attention that total XXX engagements in the last XX hours.
Engagements: XXX #
- X Week XXXXXX +76%
- X Month XXXXXX -XX%
- X Months XXXXXXX -XX%
- X Year XXXXXXXXX +3,261%
Mentions: XX #
- X Week XX +24%
- X Month XX +13%
- X Months XXX +437%
- X Year XXX +1,588%
Followers: XXXXX #
- X Week XXXXX +4.90%
- X Month XXXXX +6.90%
- X Months XXXXX +69%
- X Year XXXXX +170%
CreatorRank: XXXXXXXXX #
Social Influence
Social category influence finance XXXX%
Social topic influence $nwbo #2, $ibrx #7, science 3.85%, the first 3.85%, future 3.85%, balance sheet #1438, $4205t #78, cuomo 1.92%, elements 1.92%, the face XXXX%
Top accounts mentioned or mentioned by @jimtanaka1 @_littlefire1 @dcvaxdefender @stephenwangs73 @maveric92283613 @smyley4evr1 @metacollectiveg @drmakaryfda @ottopichler @scooterd_speaks @flyfishing15331 @alphavestcap @doc_brown2 @grok @littlefire1 @nocontextbrits @ustraderep @commercegov @potuss @drpatsoonshiong
Top assets mentioned ImmunityBio, Inc. Common Stock (IBRX)
Top Social Posts
Top posts by engagements in the last XX hours
"#MHRA Please approve $NWBO #DCVax for #GBM. Patients need access to better treatments and DCVax has already shown meaningful survival benefit with essentially no toxicity. It is time 🎄 The only real toxicity left is the delay. Patients and families deserve access now"
X Link 2025-12-04T18:18Z 1417 followers, 2757 engagements
"🧬 $NWBO 424B5 FORENSIC INTELLIGENCE REPORT ➡ TLDR The 424B5 NWBO filed on November XX 2025 is the opposite of a distressed financing. It is a regulatory-blackout pre-approval institutional-ready launch document. Across XX pages NWBO: Adds no new risk factors meaning no negative MHRA feedback existed. Repeats forward-looking disclaimers classic posture of a company expecting a material regulatory decision very soon after filing. Shows zero near-term dilution pressure in the 424B5 only 21.7M reserve shares NTBV unchanged; future A/S headroom is addressed separately in the proxy as a governance"
X Link 2025-11-26T00:44Z 1412 followers, 12.9K engagements
"The NewsNation special is not scientific evidence. It was a sponsored primetime feature centered entirely around Patrick Soon Shiong and multiple outlets have already confirmed that the program was produced in coordination with his company $IBRX. That is why the segment relied on dramatic storytelling emotional interviews and bold claims rather than controlled clinical data. Cuomo is not a scientific reviewer and NewsNation is not a peer reviewed journal. When you strip away the television format every major claim in that segment falls into one of two categories. Either it was a personal"
X Link 2025-11-30T17:30Z 1413 followers, 40.5K engagements
"$IBRX The Journal of Urology paper is meaningful for patients with papillary-only NMIBC and no one disputes that bladder preservation is important. But the paper only presents one part of the story and that context matters when discussing FDA policy. The publication covers Cohort B only where #Anktiva was given with BCG intravesically in a very specific localized disease setting. There was no control arm and the outcomes reported in Cohort B are essentially the same outcomes historically seen with BCG alone in papillary disease. If a combination produces the same results as BCG monotherapy"
X Link 2025-12-03T15:54Z 1412 followers, 3124 engagements
"Combination therapy is a valid idea in oncology but even with combinations you still have to show what each component is actually contributing. When both elements are delivered together in a single arm study and one of them is a very active backbone like BCG the design does not let you determine how much of the outcome came from the backbone and how much from the add on. That is not a criticism. It is simply how contribution of effect is established in cancer trials. This is exactly why the FDA noted that the study design limited their ability to say what Anktiva itself was adding. If the"
X Link 2025-12-03T20:52Z 1411 followers, XXX engagements
"🧬 The Shape of What Comes Next: How the 2025 GBM Vaccine Review Redefined the Science of $NWBO #DCVax Dendritic-Cell Immunotherapy TLDR In late 2025 Cancers (MDPI) published a sweeping unusually comprehensive review on glioblastoma vaccination titled Combined Tumor Cell and Lysate-Based Vaccines for Immunotherapy of Primary and Recurrent Glioblastoma (GBM). For the first time in a major peer-reviewed venue a scientific team laid out a full mechanistic blueprint explaining why glioblastoma has resisted nearly every conventional immunotherapy and what biological principles a successful vaccine"
X Link 2025-11-26T15:47Z 1416 followers, 1776 engagements
"âš Why Treating #ALC With IL-15 Does Not Cure Cancer And why the $IBRX BioShield thesis collapses in the face of immunology clinical evidence and $NWBO #DCVax biology #Lymphopenia is a recognized diagnosis. It has an ICD code. But treating absolute lymphocyte count (ALC) as if the number itself were the disease fundamentally misinterprets medicine and immunology. Lots of lab abnormalities have ICD-10 codes: Anemia Leukopenia Thrombocytopenia Electrolyte disturbances A diagnostic code does not mean the lab value is the therapeutic target. It simply means the abnormality needs evaluation not"
X Link 2025-11-29T06:46Z 1415 followers, 11.8K engagements
"The XX percent youre quoting isnt the effect of $IBRX #Anktiva. Its the effect of BCG. In the pivotal trial every CIS patient received BCG plus Anktiva and the FDA states plainly that you cannot statistically separate which drug did what. Thats why the agency also wrote that the median duration of response is not a reliable estimate because nearly two thirds of responders were censored. When Anktiva was tested without BCG in Cohort C the response rate was zero. And when BCG alone was compared to BCG plus a strong immunotherapy in the randomized ALBAN trial the curves were identical and the"
X Link 2025-11-29T22:18Z 1416 followers, XXX engagements
"@NoContextBrits The Cure for cancer. $NWBO #DCVax"
X Link 2025-11-30T22:34Z 1416 followers, 1303 engagements
"The Turning of the Gate: How the USUK Drug Pricing Pact Reshapes $NWBO #DCVax Commercial Landscape The December X 2025 USUK pharmaceutical pricing agreement represents more than a trade compromise. It marks the moment Britain rewired its economic architecture for Advanced Therapy Medicinal Products (ATMPs) creating a reimbursement environment built for therapies with durable survival curves and long-tail benefit. The policy never mentions DCVax-L by name. It did not need to. The agreements structural adjustments align so precisely with Northwest Biotherapeutics (NWBO) positioning that the"
X Link 2025-12-01T23:19Z 1416 followers, 5131 engagements
"What the data actually show is that $IBRX #Anktiva on its own did not just fail to help. In many cases it produced outcomes worse than what you would expect from BCG alone. That is the central fact everything else has to orbit. If a drug claims to restore or boost immune cells yet performs below the historical baseline of BCG then the biology is not behaving the way the mechanism promises. It is that simple and that fundamental. This mirrors the same clinical principles used across medicine. You do not treat a number. A hemoglobin of X means hemorrhage in trauma renal failure in chronic"
X Link 2025-12-04T10:33Z 1415 followers, 1290 engagements
"🧬 $NWBO #DCVax and the Map of the Neutrophil World How a Single Nature Paper Quietly Validated the Myeloid Logic of DCVax TL;DR A new Nature paper has built the first true map of the neutrophil world (NeuMap) a universal coordinate system showing that neutrophils move between a small number of predictable functional hubs depending on cytokine signals. Tumors hijack this map by pulling neutrophils into two suppressive pro-angiogenic hubs (IS-I and IS-II). Interferons pull them into anti-tumor hubs. Under the right conditions neutrophils can even become antigen-presenting cells (APCs).123 Once"
X Link 2025-12-04T18:13Z 1416 followers, 1600 engagements
"$NWBO #DCVax stands out even more under the new HHS AI Strategy HHS just unveiled its AI plan and it changes everything about how cancer data will be analyzed If you handed an AI every cancer study and told it to answer one question What actually works it would see the pattern immediately Most oncology drugs create small fragile gains with high toxicity #NWBO #DCVax produces durable immune control across tumors with almost none An AI trained to merge trial data real world evidence and survival curves would flag the same signal again and again Long tail survivors Consistent effect across"
X Link 2025-12-04T20:19Z 1416 followers, 1716 engagements
"You actually can say patients do just as well and sometimes better with proper BCG re-induction because the actual numbers support it. Many people labeled BCG-failed arent biologically refractory; they simply didnt meet the response window after their first induction. When those same patients receive a true second induction of BCG outcomes are strong. In a modern multi-center study XXXX% of re-induced patients achieved a complete response and XXXX% of those responders remained disease-free at XX months. The MSK double-induction protocol showed even stronger results: XX% complete response at 6"
X Link 2025-12-05T02:48Z 1416 followers, XX engagements
"I get the frustration but the FDA is actually showing its hand here. The Plausible Mechanism Pathway was co written by the current FDA Commissioner and published in the NEJM. It was designed for platforms with a clear mechanism plus real world evidence. That is exactly where $NWBO sits with a completed pivotal Phase III and years of expanding RWE. The agency is not lowering the bar. It is shifting to a framework that DCVax L already fits one that allows real world evidence to support tissue agnostic deployment"
X Link 2025-12-05T14:13Z 1416 followers, XXX engagements
"Cant disagree with that 😅 Its a good thing LP chose the UK for first approval. The MHRA has already built the framework for RWE driven tissue agnostic immunotherapies and DCVax fits that model better than anything in big pharmas pipeline. The move protected the science and positions NWBO to come back to the FDA from a position of strength"
X Link 2025-12-05T14:23Z 1415 followers, XX engagements
"Youre absolutely right to ground this conversation in Jim Allisons work because CTLA-4 blockade only succeeds when tumor antigens are already being properly presented. That is why CTLA-4 and PD-1 inhibitors produce long-tail survival in melanoma and other cancers. They do not make the immune system stronger. They remove brakes from an immune system that already recognizes the tumor. That recognition step is the key difference between checkpoint blockade and an IL-15 agonist. This is exactly the principle the UCLA group including Liau Prins and Mulholland has spent their careers building on."
X Link 2025-12-06T00:27Z 1415 followers, XX engagements
"🧬 #FDA Just Revealed the Exact Pathway $NWBO #DCVax-L Needs The new FDA Grand Rounds isnt about DCVax but it is about the regulatory engine DCVax-L runs on. On December XX the Agency is dedicating an entire session to Real-World Evidence (RWE)how to validate it how to judge external controls and how to use it in oncology approvals when traditional RCTs are impossible. That matters because DCVax-Ls Phase X trial used: an external control arm a crossover-contaminated dataset and survival outcomes proven through RWE-strength comparisons The invited speaker Dr. Marie Bradley is the FDAs senior"
X Link 2025-12-03T00:34Z 1417 followers, 8357 engagements
"$NWBO #DCVax and the Making of Eden How Zeon Edge Curate and Sawston Rebuilt the Future of Immunotherapy From the outside Northwest Biotherapeutics has long appeared easy to dismiss. The name is cumbersome. The companys balance sheet rarely invited envy. Analysts accustomed to clean small-molecule pipelines saw instead a Phase III glioblastoma trial that defied conventional oncology norms wrapped inside a cell therapy so personalized and so delicate that even well-capitalized companies have struggled to scale anything like it. To many the story looked familiar: an interesting data set some"
X Link 2025-12-04T03:55Z 1416 followers, 1850 engagements
"@maveric92283613 @maveric92283613 this narrative I posted is actually based on the court filing"
X Link 2025-12-05T18:30Z 1417 followers, XXX engagements
"This entire claim has no basis in evidence and none of the statements being made about N-803 are supported by clinical data regulatory filings or basic immunology. $IBRX #Anktiva is an IL-15 agonist that expands NK and CD8 cells but immune expansion is not the same as curing cancer clearing viruses fixing antibiotic resistance or extending human lifespan. In every cancer where outcomes can be compared to a known backbone N-803 has failed to show any independent therapeutic effect. In pancreatic cancer it matched third-line chemotherapy. In NSCLC it matched treatment-beyond-progression on"
X Link 2025-12-06T11:07Z 1417 followers, XXX engagements